BCT

U.S. Army Awards TRX Systems $402 Million Production Contract for DAPS GEN II

Retrieved on: 
Thursday, May 4, 2023
Intelligence, DAGR, GPS, PEO, Brigade combat team, PM, Army, Agility, Soldier, Navigation, Assurance, IDIQ, MDO, QRC, Indefinite, Defense Advanced GPS Receiver, TRX, Risk, United States Department of the Army, TRX System, BCT, PNT, Safety, Satellite navigation device, Explosive, Timing, Positioning, NW

GREENBELT, Md., May 4, 2023 /PRNewswire-PRWeb/ -- TRX Systems has been awarded a $402 Million, seven-year, Indefinite Delivery/Indefinite Quantity (IDIQ) contract by the U.S. Army for the procurement of Dismounted Assured Positioning, Navigation, and Timing System Generation II systems and services (DAPS GEN II). The award to TRX is a Program of Record contract from the U.S. Army Program Executive Office for Intelligence, Electronic Warfare and Sensors (PEO IEW&S) for delivery of systems that provide Assured PNT to Soldiers operating in GPS denied or contested environments.

Key Points: 
  • The DAPS GEN II systems developed and delivered by TRX will provide Assured PNT to warfighters, enabling seamless dismounted operations in GPS-denied environments.
  • GREENBELT, Md., May 4, 2023 /PRNewswire-PRWeb/ -- TRX Systems has been awarded a $402 Million, seven-year, Indefinite Delivery/Indefinite Quantity (IDIQ) contract by the U.S. Army for the procurement of Dismounted Assured Positioning, Navigation, and Timing System Generation II systems and services (DAPS GEN II).
  • The TRX Systems solution to be provided under the contract, known as TRX DAPS II, enables dismounted maneuver operations with speed, surprise, and agility, even where GPS is compromised or denied.
  • "The Assured PNT information provided by TRX DAPS II will secure dismounted Army forces' ability to shoot, move, and communicate in GPS challenged environments."

Quantum Leap Healthcare Collaborative Announces Mobile Platform Launch of its Clinical Trial Matching Service

Retrieved on: 
Tuesday, April 25, 2023
Database, Internet, Clinical trial, Cancer, MTS, Organization, Patient, SAN, Quantum Leap, BCT, Breast cancer, Pharmaceutical industry

SAN FRANCISCO, April 25, 2023 /PRNewswire/ -- Quantum Leap Healthcare Collaborative (QLHC) announces the mobile responsive launch of its metastatic breast cancer clinical trial matching service, Metastatic Trial Search (MTS).

Key Points: 
  • SAN FRANCISCO, April 25, 2023 /PRNewswire/ -- Quantum Leap Healthcare Collaborative (QLHC) announces the mobile responsive launch of its metastatic breast cancer clinical trial matching service, Metastatic Trial Search (MTS).
  • Clinical trials provide an opportunity for patients to have access to promising new therapies; with a mobile responsive version of the trial matching app, Metastatic Trial Search is now more accessible to more individuals.
  • MTS is powered by CTMatch, Quantum Leap's second-generation clinical trial matching platform, developed by the team that founded and runs BreastCancerTrials.org (BCT).
  • Operating since 2008, BCT is one of the longest-running, most robust and comprehensive trial matching services for breast cancer patients.

POTOMAC BANCSHARES, INC. REPORTS 2023 FIRST QUARTER RESULTS

Retrieved on: 
Monday, April 24, 2023
Insurance, Treasury, Total, FHLB, ERM, Community banking models, Tax, AFS, FDIC, Sale, Compact disc, PPP, ROA, Community, The Company, Federal Reserve, Risk, CECL, OTC, Growth, Bank, BCT, ROE, Geography, Cryptocurrency, Beauty salon, Mobile phone, Video game, Self storage, Real estate, Reinsurance, Life insurance, Investment, Visa

Investment securities were $88.6 million as of Q1 2023, compared to $88.4 million as of Q1 2022.

Key Points: 
  • Investment securities were $88.6 million as of Q1 2023, compared to $88.4 million as of Q1 2022.
  • Net interest income was $6.5 million for the quarter compared to $5.2 million in the first quarter of 2022, and $6.8 million in Q4 2022.
  • Return on Assets (ROA) for the first quarter 2023 was 1.09% compared to 0.95% in the first quarter of 2022, and 1.13% in the linked quarter.
  • Return on Equity (ROE) for the first quarter was 13.52% compared to 11.14% in the first quarter of 2022, and 14.74% in the linked quarter.

POTOMAC BANCSHARES, INC. DECLARES QUARTERLY DIVIDEND

Retrieved on: 
Thursday, April 20, 2023
Bank, BCT, OTC, Holding company, Security (finance)

CHARLES TOWN, W.Va., April 20, 2023 /PRNewswire/ -- The Board of Directors of Potomac Bancshares, Inc. (the "Company") (OTC:PTBS), the one bank holding company for Bank of Charles Town (BCT), declared at their April Board meeting a quarterly dividend of $0.09 per share.

Key Points: 
  • CHARLES TOWN, W.Va., April 20, 2023 /PRNewswire/ -- The Board of Directors of Potomac Bancshares, Inc. (the "Company") (OTC:PTBS), the one bank holding company for Bank of Charles Town (BCT), declared at their April Board meeting a quarterly dividend of $0.09 per share.
  • The dividend is for all shareholders of record on May 3, 2023 and will be paid on May 10, 2023.

BriaCell Presents Positive Data Demonstrating Survival and Clinical Benefits in Advanced Metastatic Breast Cancer at the 2023 AACR

Retrieved on: 
Monday, April 17, 2023
AACR, University, Orange County Convention Center, Survival, Cancer, Quality of life, Progression-free survival, Immunotherapy, Associate, PFS, Medicine, HR, Death, DTH, Patient, Immune system, GM-CSF, TSX, Financial toxicity, PD-1, Pembrolizumab, Therapy, BCT, Pharmaceutical industry, Vaccine, Medical imaging

Continued positive clinical data suggests more meaningful survival and clinical benefits in advanced metastatic breast cancer.

Key Points: 
  • Continued positive clinical data suggests more meaningful survival and clinical benefits in advanced metastatic breast cancer.
  • “With over 40,000 annual deaths in the U.S. alone, advanced metastatic breast cancer remains an unmet medical need.
  • Hormone Receptor Positive (HR+) Patients: Survival and clinical benefits were observed across multiple subtypes of advanced metastatic breast cancer patients, especially in patients with hormone receptor positive (HR+) cancer, a very large segment of the patient population.
  • Both posters show potential easy to conduct diagnostic tests to predict clinical benefit in patients with advanced metastatic breast cancer.

Raytheon Technologies subsidiary, Blue Canyon Technologies, Wins Award from Jet Propulsion Laboratory to Provide Microsatellites for INCUS Mission

Retrieved on: 
Thursday, April 13, 2023
Constellation, Raytheon Technologies, Weather, Jet Propulsion Laboratory, NASA, BCT, NYSE, Communications satellite

LAFAYETTE, Colo., April 13, 2023 /PRNewswire/ -- Small satellite manufacturer and mission services provider Blue Canyon Technologies, a Raytheon Technologies (NYSE: RTX) subsidiary, will design and manufacture three microsatellites to support NASA's Investigation of Convective Updrafts, or INCUS, mission. The INCUS mission – led by NASA's Jet Propulsion Laboratory – aims to better understand the complex dynamics of thunderstorms and their impact on Earth's climate and weather models.

Key Points: 
  • LAFAYETTE, Colo., April 13, 2023 /PRNewswire/ -- Small satellite manufacturer and mission services provider Blue Canyon Technologies , a Raytheon Technologies (NYSE: RTX) subsidiary, will design and manufacture three microsatellites to support NASA's Investigation of Convective Updrafts, or INCUS, mission.
  • The INCUS mission – led by NASA's Jet Propulsion Laboratory – aims to better understand the complex dynamics of thunderstorms and their impact on Earth's climate and weather models.
  • Blue Canyon's microsats will fly in tandem coordination, each displaying a dynamic atmospheric radar and dynamic microwave radiometer measuring the atmospheric conditions of Earth.
  • "BCT's successful science exploration programs and our experience controlling large flexible structures will be key to supporting this critical science mission," said Jeff Schrader, president of Blue Canyon Technologies.

BCT-Bank of Charles Town Appoints Krystle Burkhart as Commercial Business Development Officer for the Eastern Panhandle of West Virginia

Retrieved on: 
Friday, April 7, 2023
Partnership, Girl Scout National Center West, Musselman High School, Senior, Dime Community Bank, Relay For Life, Muscular dystrophy, EVP, AAS, Mock interview, The Lighthouse Project, Assistant, Krystle Carrington, Organization, Truist, Business administration, Fashion Retail Academy, Community, Muscular Dystrophy Association, International Red Cross and Red Crescent Movement, OTC, McCann School of Business & Technology, Vladimir Putin, Bank, BCT, BB, Federal Capital women's cricket team, Teller

CHARLES TOWN, W.Va., April 7, 2023 /PRNewswire/ -- (OTC:PTBS) – BCT-Bank of Charles Town, also known as The Community's Bank, recently announced the appointment of Krystle Burkhart to the position of Commercial Business Development Officer.

Key Points: 
  • CHARLES TOWN, W.Va., April 7, 2023 /PRNewswire/ -- (OTC:PTBS) – BCT-Bank of Charles Town, also known as The Community's Bank, recently announced the appointment of Krystle Burkhart to the position of Commercial Business Development Officer.
  • Ms. Burkhart will be responsible for acquiring new commercial clients and developing stronger relationships with current commercial clients.
  • She will report to Aaron Howell, Senior Vice President and Community Banking Executive and focus on the Eastern Panhandle region of West Virginia.
  • "We are excited to have Krystle join our Eastern Panhandle team," stated Raymond Goodrich, EVP and Chief Lending Officer.

BriaCell Announces Intention to Spin-Out Certain Pre-Clinical Assets into a Newly Created “SpinCo” Entity whereby Shareholders to Receive One New Share of “SpinCo” in Addition to Each Current Share of BriaCell Already Held

Retrieved on: 
Thursday, March 30, 2023
LLP, Minority, Model Business Corporation Act, Cancer, The Act, Transaction, CFO, TSX, Toronto Stock Exchange, Therapy, BCT, Security (finance), Cryptocurrency, Corporate spin-off

On closing of the Transaction, it is anticipated that the SpinCo Assets will be majority-owned, controlled, and governed by BriaCell and owned by BriaCell shareholders of record who will receive SpinCo Shares as defined herein.

Key Points: 
  • On closing of the Transaction, it is anticipated that the SpinCo Assets will be majority-owned, controlled, and governed by BriaCell and owned by BriaCell shareholders of record who will receive SpinCo Shares as defined herein.
  • SpinCo Shares issued to BriaCell shareholders will comprise 33.33% ownership of SpinCo Shares upon closing of the Transaction.
  • BriaCell believes that the Transaction will increase shareholder value by allowing capital markets to ascribe value to the SpinCo Assets independently of BriaCell’s core immunotherapy assets.
  • SpinCo will provide an opportunity for SpinCo Assets to be funded and developed on their own.

Evolution of Oncology Treatments Giving New Hope to Those Diagnosed with Breast Cancer

Retrieved on: 
Friday, March 24, 2023
Survival rate, Treatment, Survival, Fulvestrant, CDK2, Patient, Risk, News, Breast Cancer Awareness Month, Breast, Minerva Surgical, Inc. v. Hologic, Inc., ONC, TSX, Diagnosis, FDA, Cancer, Immunotherapy, PFS, Șaeș, HR, Lymph, Therapy, ORR, HOLX, Progression-free survival, Clinical trial, Paclitaxel, Woman, Fast track (FDA), OFS, Nature, Breast cancer, American Cancer Society, Recurrence, BCT, Tamoxifen, Pharmaceutical industry, Birth control, Medical imaging, Nursing, Hologic, Oncolytics Biotech

VANCOUVER, British Columbia, March 24, 2023 /PRNewswire/ -- USA News Group - Treatments for various forms of breast cancer continue to evolve, with several new breakthroughs being labeled as landmark in nature and giving hope to families dealing with a fateful diagnosis. According to the American Cancer Society in 2022, the 5-year relative survival rate for localized breast cancer, cancer that has not spread outside the breast, is 99%, and for those whose cancer has spread outside the breast to nearby structures or lymph nodes, the survival rate is 86%. Over the last year, the biotech sector has increased its efforts and delivered very optimistic data from such groups as Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), CytomX Therapeutics, Inc. (NASDAQ: CTMX), BriaCell Therapeutics (NASDAQ: BCTX) (NASDAQ: BCTXW) (TSX: BCT), Relay Therapeutics (NASDAQ: RLAY), and Hologic, Inc. (NASDAQ: HOLX).

Key Points: 
  • According to the American Cancer Society in 2022, the 5-year relative survival rate for localized breast cancer, cancer that has not spread outside the breast, is 99%, and for those whose cancer has spread outside the breast to nearby structures or lymph nodes, the survival rate is 86%.
  • This pivotal registration study will be enrolling advanced metastatic breast cancer patients for whom no approved treatment options exist.
  • Hologic's data showed that the Breast Cancer Index test identified which premenopausal patients with early-stage HR+ breast cancer benefited from the addition of ovarian function suppression (OFS) to primary adjuvant endocrine therapy.
  • The Breast Cancer Index test is the first biomarker to be evaluated in a cohort from the landmark Suppression of Ovarian Function Trial (SOFT).

Evolution of Oncology Treatments Giving New Hope to Those Diagnosed with Breast Cancer

Retrieved on: 
Friday, March 24, 2023
Survival rate, Treatment, Survival, Fulvestrant, CDK2, Patient, Risk, News, Breast Cancer Awareness Month, Breast, Minerva Surgical, Inc. v. Hologic, Inc., ONC, TSX, Diagnosis, FDA, Cancer, Immunotherapy, PFS, Șaeș, HR, Lymph, Therapy, ORR, HOLX, Progression-free survival, Clinical trial, Paclitaxel, Woman, Fast track (FDA), OFS, Nature, Breast cancer, American Cancer Society, Recurrence, BCT, Tamoxifen, Pharmaceutical industry, Birth control, Medical imaging, Nursing, Hologic, Oncolytics Biotech

VANCOUVER, British Columbia, March 24, 2023 /PRNewswire/ -- USA News Group - Treatments for various forms of breast cancer continue to evolve, with several new breakthroughs being labeled as landmark in nature and giving hope to families dealing with a fateful diagnosis. According to the American Cancer Society in 2022, the 5-year relative survival rate for localized breast cancer, cancer that has not spread outside the breast, is 99%, and for those whose cancer has spread outside the breast to nearby structures or lymph nodes, the survival rate is 86%. Over the last year, the biotech sector has increased its efforts and delivered very optimistic data from such groups as Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), CytomX Therapeutics, Inc. (NASDAQ: CTMX), BriaCell Therapeutics (NASDAQ: BCTX) (NASDAQ: BCTXW) (TSX: BCT), Relay Therapeutics (NASDAQ: RLAY), and Hologic, Inc. (NASDAQ: HOLX).

Key Points: 
  • According to the American Cancer Society in 2022, the 5-year relative survival rate for localized breast cancer, cancer that has not spread outside the breast, is 99%, and for those whose cancer has spread outside the breast to nearby structures or lymph nodes, the survival rate is 86%.
  • This pivotal registration study will be enrolling advanced metastatic breast cancer patients for whom no approved treatment options exist.
  • Hologic's data showed that the Breast Cancer Index test identified which premenopausal patients with early-stage HR+ breast cancer benefited from the addition of ovarian function suppression (OFS) to primary adjuvant endocrine therapy.
  • The Breast Cancer Index test is the first biomarker to be evaluated in a cohort from the landmark Suppression of Ovarian Function Trial (SOFT).